Stockscreener 앱 받기
0.00
100.00%
-5.54
시간 외 거래:
5.54
5.54
+
Alimera Sciences Inc 주식(ALIM)의 최신 뉴스
Alimera Sciences Announces Data from 19 Iluvien(R) Studies to be Presented at 2018 ARVO - ACCESS Newswire
ALIMERA SCIENCES INC to Host Earnings Call - ACCESS Newswire
Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal - MSN
Actinic Keratosis Treatment Market 2034: EMA, PDMA, FDA Approvals, Prevalence, Clinical Trials, Medication, Therapies, and Companies by DelveInsight - The Globe and Mail
ANIPANI Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity - The Manila Times
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc.ALIM - GuruFocus.com
Autoimmune Uveitis Market Will Accelerate Rapidly with - openPR
Uveitis Market Forecasted for Major Expansion by 2031 | Novartis - openPR
Eye Inflammation Treatment Market Overall Study Report - openPR
Diabetic Macular Edema Market Key Players AnalysisNovartis - openPR
Ophthalmic Steroids Drugs Market 2024-2031 Porter's Five - openPR
ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance - GlobeNewswire
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06% - GlobeNewswire
ANI Pharmaceuticals introduces generic Estradiol Gel By Investing.com - Investing.com South Africa
ANI Pharmaceuticals introduces generic Estradiol Gel - Investing.com
ANI Pharmaceuticals to Present New Data Highlighting - GlobeNewswire
ANI Pharmaceuticals to Present New Data Highlighting Membranous Nephropathy Research at American Society of Nephrology Kidney Week 2024 - StockTitan
ANI Pharmaceuticals price target raised to $62 from $60 at Truist - Yahoo Finance
ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market - Seeking Alpha
StockNews.com Begins Coverage on Alimera Sciences (NASDAQ:ALIM) - Defense World
Stonepine Capital Management LLC Sells 539,256 Shares of Alimera Sciences, Inc. (NASDAQ:ALIM) - Defense World
20,394 Shares in Alimera Sciences, Inc. (NASDAQ:ALIM) Acquired by Rhumbline Advisers - Defense World
Alimera Sciences (NASDAQ:ALIM) Coverage Initiated at StockNews.com - Defense World
ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconazole Shampoo, 2% - StockTitan
On the Move: Mergers, Management Moves, and More - Community News
Glazer Capital LLC Makes New $3.07 Million Investment in Alimera Sciences, Inc. (NASDAQ:ALIM) - Defense World
Allarity Therapeutics, Inc Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Allarity Therapeutics, - Longview News-Journal
ALXO stock touches 52-week low at $1.87 amid market challenges - Investing.com
ALLR CLASS ACTION REMINDERRobbins LLP Reminds - GlobeNewswire
Great Point Partners LLC Increases Stake in Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Stocks Under $20: Arlo Technologies, Applied Optoelectronics - Schaeffers Research
Allison Transmission (NYSE:ALSN) Reaches New 1-Year High at $92.93 - MarketBeat
Market Watch: Alignment Healthcare Inc (ALHC)’s Noteworthy Drop, Closing at 10.98 - The Dwinnex
What is the investor’s view on Alx Oncology Holdings Inc (ALXO)? - US Post News
A stock that deserves closer examination: Allarity Therapeutics Inc (ALLR) - US Post News
Berkley W R Corp Purchases New Shares in Alchemy Investments Acquisition Corp 1 (NASDAQ:ALCY) - MarketBeat
Market Momentum: Allarity Therapeutics Inc (ALLR) Registers a 1.36 Increase, Closing at 2.24 - The Dwinnex
Intech Investment Management LLC Has $1.74 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Rhumbline Advisers Purchases 87 Shares of Alexander’s, Inc. (NYSE:ALX) - Defense World
Insider Sale Alert: Aldeyra Therapeutics Inc [ALDX] – Is it Time to sell? - Knox Daily
ALLR Investors Have Opportunity to Lead Allarity Therapeutics, Inc. Securities Fraud Lawsuit - The Bubble
Elevai Labs shares tumble on pricing of new stock offering - The Business Journals
Alector (NASDAQ:ALEC) Shares Down 5.6% - Defense World
Integral Health Asset Management LLC Buys 20,000 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
ALLR INVESTOR ALERT: Edelson Lechtzin LLP Urges Allarity - GlobeNewswire
Alignment Healthcare (NASDAQ:ALHC) Shares Gap Down to $11.43 - Defense World
Market Update: Alx Oncology Holdings Inc (ALXO) Sees Negative Movement, Closing at 2.07 - The Dwinnex
Wall Street analysts’ outlook for Arcellx Inc (ACLX) - SETE News
In the Green: Longboard Pharmaceuticals Inc (LBPH) Closes at 33.89, Up/Down 1.47 from Previous Day - The Dwinnex
Why Elevai Labs (ELAB) Stock Is Down 60% Today - Benzinga
Ally Bridge Group NY LLC Reduces Holdings in Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) - Defense World
Was Longboard Pharmaceuticals Inc (LBPH)’s session last reading good? - US Post News
Alternus Clean Energy outlines plan to regain Nasdaq compliance - Proactive Investors UK
Get in on Aldeyra Therapeutics Inc’s (ALDX) buy-in window today! - SETE News
Elevai Labs announces pricing of $8 million public offering - MSN
(((O))) Review: Alunah – Fever Dream - Echoes And Dust
Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) - PR Newswire
1.76%
1.79%
자본화:
|
볼륨(24시간):